Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Love Letter To Red !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by HighSkies2019on Aug 03, 2022 1:41pm
230 Views
Post# 34868699

Love Letter To Red !!!

Love Letter To Red !!!Awe Red there was just so many songs I wanted to send you to tell you how I feel. I am sorry your missing me. I am sorry for not giving you the attention your longing for . I am sorry that you are making investing decisions based off total strangers . What I am not sorry for is that dumb F_ _ K that I blocked in last week cause he stold my wallet all my I.D and used my bank card ....Now that guy was really sorry that he ripped off this physco ... never did he think he would get caught but the silver braclets the cops gifted him with were a little tighter then the last time he wore them ....so get me Rob's lisence plate let me see if he will confess... this guy was so sorry he was handing over Big Brown Bills ...just saying he was sorry !!! .... Red I am so sorry...I miss you to !
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities